Alaunos Therapeutics (WEK0) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ad-Rts-Hil-12, Veledimex, Cemiplimab-Rwlc | Glioblastoma | Phase II | Terminated | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Jun 28, 2019 | ― |
| Ad-Rts-Hil-12, Veledimex | Glioblastoma | Phase I | Completed | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Aug 29, 2018 | ― |
| Nivolumab, Ad-Rts-Hil-12, Veledimex | Glioblastoma | Phase I | Completed | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Jul 05, 2018 | ― |
| Ad-Rts-Hil-12, Oral Veledimex - Arm 1, Oral Veledimex - Arm 2 | Diffuse Intrinsic Pontine Glioma, Pediatric Brain Tumor | phase1AndPhase2 | Terminated | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Oct 16, 2017 | ― |
| Ad-Rts-Hil-12, Veledimex | Metastatic Breast Cancer | phase1AndPhase2 | Terminated | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Apr 06, 2015 | ― |
| Ad-Rts-Hil-12, Veledimex | Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | Phase I | Completed | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Dec 16, 2013 | ― |
| Ad-Rts-Hil-12 And Veledimex, Palifosfamide | Breast Cancer Nos Metastatic Recurrent | Phase II | Terminated | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | Aug 29, 2012 | ― |
| Carboplatin, Etoposide, Palifosfamide-Tris | Extensive-Stage Small Cell Lung Cancer | Phase III | Terminated | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) | Mar 12, 2012 | ― |
| Doxorubicin In Combination With Palifosfamide-Tris | Soft Tissue Sarcoma | Phase III | Terminated | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | Jul 21, 2010 | ― |
| Indibulin | Metastatic Breast Cancer | Phase I | Terminated | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | Apr 08, 2010 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ad-Rts-Hil-12, Veledimex, Cemiplimab-Rwlc | Phase II | Glioblastoma | Terminated | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Jun 28, 2019 | ― |
| Ad-Rts-Hil-12, Veledimex | Phase I | Glioblastoma | Completed | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Aug 29, 2018 | ― |
| Nivolumab, Ad-Rts-Hil-12, Veledimex | Phase I | Glioblastoma | Completed | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Jul 05, 2018 | ― |
| Ad-Rts-Hil-12, Oral Veledimex - Arm 1, Oral Veledimex - Arm 2 | phase1AndPhase2 | Diffuse Intrinsic Pontine Glioma, Pediatric Brain Tumor | Terminated | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Oct 16, 2017 | ― |
| Ad-Rts-Hil-12, Veledimex | phase1AndPhase2 | Metastatic Breast Cancer | Terminated | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Apr 06, 2015 | ― |
| Ad-Rts-Hil-12, Veledimex | Phase I | Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | Completed | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Dec 16, 2013 | ― |
| Ad-Rts-Hil-12 And Veledimex, Palifosfamide | Phase II | Breast Cancer Nos Metastatic Recurrent | Terminated | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | Aug 29, 2012 | ― |
| Carboplatin, Etoposide, Palifosfamide-Tris | Phase III | Extensive-Stage Small Cell Lung Cancer | Terminated | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) | Mar 12, 2012 | ― |
| Doxorubicin In Combination With Palifosfamide-Tris | Phase III | Soft Tissue Sarcoma | Terminated | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | Jul 21, 2010 | ― |
| Indibulin | Phase I | Metastatic Breast Cancer | Terminated | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | Apr 08, 2010 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alaunos Therapeutics Inc (DE:WEK0) have in its pipeline
Alaunos Therapeutics DE:WEK0 is currently developing the following drugs: Ad-Rts-Hil-12, Veledimex, Cemiplimab-Rwlc, Ad-Rts-Hil-12, Veledimex, Nivolumab, Ad-Rts-Hil-12, Veledimex, Ad-Rts-Hil-12, Oral Veledimex - Arm 1, Oral Veledimex - Arm 2, Ad-Rts-Hil-12 And Veledimex, Palifosfamide, Carboplatin, Etoposide, Palifosfamide-Tris, Doxorubicin In Combination With Palifosfamide-Tris, Indibulin, Capecitabine, Indibulin, Doxorubicin, Palifosfamide Tris And Doxorubicin, Zio-201, Darinaparsin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
